Publication | Closed Access

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

UrologyPhase Ii TrialGenitourinary CancerCabazitaxel Versus AbirateroneMedicinePharmacologyClinical TrialsPharmacotherapyCancer TreatmentProstatic DiseaseOncology